

RESEARCH

Open Access

Metabolic and anthropometric parameters contribute to ART-mediated CD4⁺ T cell recovery in HIV-1-infected individuals: an observational study

Livio Azzoni^{1†}, Andrea S Foulkes^{2†}, Cynthia Firnhaber³, Xiangfan Yin¹, Nigel J Crowther⁴, Deborah Glencross⁵, Denise Lawrie⁵, Wendy Stevens⁵, Emmanouil Papasavvas¹, Ian Sanne³ and Luis J Montaner^{1*}

Abstract

Background: The degree of immune reconstitution achieved in response to suppressive ART is associated with baseline individual characteristics, such as pre-treatment CD4 count, levels of viral replication, cellular activation, choice of treatment regimen and gender. However, the combined effect of these variables on long-term CD4 recovery remains elusive, and no single variable predicts treatment response. We sought to determine if adiposity and molecules associated with lipid metabolism may affect the response to ART and the degree of subsequent immune reconstitution, and to assess their ability to predict CD4 recovery.

Methods: We studied a cohort of 69 (48 females and 21 males) HIV-infected, treatment-naïve South African subjects initiating antiretroviral treatment (d4T, 3Tc and lopinavir/ritonavir). We collected information at baseline and six months after viral suppression, assessing anthropometric parameters, dual energy X-ray absorptiometry and magnetic resonance imaging scans, serum-based clinical laboratory tests and whole blood-based flow cytometry, and determined their role in predicting the increase in CD4 count in response to ART.

Results: We present evidence that baseline CD4⁺ T cell count, viral load, CD8⁺ T cell activation (CD95 expression) and metabolic and anthropometric parameters linked to adiposity (LDL/HDL cholesterol ratio and waist/hip ratio) significantly contribute to variability in the extent of CD4 reconstitution (Δ CD4) after six months of continuous ART.

Conclusions: Our final model accounts for 44% of the variability in CD4⁺ T cell recovery in virally suppressed individuals, representing a workable predictive model of immune reconstitution.

Background

Chronic HIV infection is characterized by progressive loss of CD4⁺ T cells; suppression of viral replication with antiretroviral agents results in most subjects in rapid CD4 recovery [1] and decreased T cell activation (e.g., CD38 expression [2]). Defective early recovery has been demonstrated to be associated with increased morbidity [3]; however, the extent of this recovery over time is difficult to predict, as it likely depends on multiple factors.

Baseline CD4⁺ T cell count remains the most relevant predictor of clinical progression and survival in subjects on antiretroviral therapy (ART) [4-8], but by itself it has been shown to inadequately account for the variability in ART-mediated immune restoration, and “on treatment” assessment of CD4⁺ T cells retains a better prognostic value [9]. Other factors positively associated with CD4⁺ T cell immune reconstitution include the presence of specific genotypes, such as Δ ₃₂CCR5 [10], antiretroviral regimen [11] and, in some studies, pre-ART viral load [12].

Immune activation of the T cell compartment (e.g., CD8⁺ T cells), alterations of memory T cell subsets and depletion of innate immune subsets (e.g., NK and

* Correspondence: montaner@mail.wistar.org

† Contributed equally

¹HIV-1 Immunopathogenesis Laboratory, the Wistar Institute, Philadelphia, PA, USA

Full list of author information is available at the end of the article

dendritic cells) are associated with advanced HIV infection [1,13-17]; however, while most of these cell subsets are at least partially recovered on ART, even though with different kinetics, their potential association with early CD4 recovery has not been explored.

In addition to viral and immunologic parameters, metabolic factors have been shown to be associated with disease progression, and are putative candidates to predict CD4 recovery: advanced HIV infection (i.e., low CD4 counts) is associated with chronic inflammation and increased immune activation, with alteration of metabolic parameters associated with lipid metabolism and increased atherogenic risk (as assessed by increased carotid intima-media thickness) in subjects of both sexes [18,19]. A number of studies have reported that subjects with advanced HIV infection have lower high-density lipoprotein (HDL) cholesterol, higher low-density lipoprotein (LDL) cholesterol and triglycerides [20,21], and CD4 counts appear to directly correlate with HDL cholesterol [22,23].

The existence of a relationship between metabolic markers, viremia and immune activation is also suggested by the observation that ART-mediated suppression of HIV replication results in a rapid normalization of a number of markers linked to cardiovascular risk [24].

While these observations highlight the negative effects of HIV infection on lipid metabolism and overall atherogenic risk, it is of note that cohort-based observations indicate that high adiposity (which is normally associated with insulin resistance, dyslipidemia and atherogenesis) might be beneficial for HIV-infected individuals, contributing to lower steady state viral replication and slower disease progression [25,26]. Altogether, these observations suggest that adipose tissue accumulation and distribution may affect the immunological host/virus equilibrium in chronic HIV infection; however, the impact of adiposity on ART-mediated immune reconstitution remains undefined.

In a reported multivariate analysis, subject age, nadir and baseline CD4 count and initial viral load were found to be inversely associated with early CD4 response to suppressive ART [12]; importantly, the predictive value of subject gender was ascribed to its effect on baseline CD4 measurements [12,27]. Predictive logistic regression models for incomplete CD4 response have been developed, based on subject age, baseline CD4⁺ T cell count and early CD4 response [28]; however, to our knowledge, there are at present no satisfactory models that adequately predict early (less than six months) CD4⁺ T cell immune reconstitution. To our knowledge, adiposity-associated metabolic markers (e.g., BMI, serum lipid fractions, HOMA-2), have not been used in these models, and their predictive role remains unclear.

Based on the reported association of viremia and CD4 counts with body mass index (BMI) and serum lipid

levels, we sought to determine: (1) if adiposity and markers associated with lipid metabolism can affect the degree of early (six months [3]) immune reconstitution after ART; and (2) if metabolic parameters could contribute to a predictive model for immune reconstitution that includes pre-ART viral, immune activation and CD4⁺ T cell counts. The present study followed a cohort of ART-naïve, HIV-infected South African subjects. We demonstrate that metabolic parameters measured before ART have a significant effect on the degree of immune reconstitution attained after six months of continuous ART and contribute significantly to a predictive model of CD4⁺ T cell immune reconstitution.

Methods

Study subjects

We assessed 69 ART-naïve, HIV-infected subjects initiating ART (d4T, 3TC and lopinavir/ritonavir) at the Clinical HIV Research Unit of the Themba Lethu Clinic, Johannesburg, South Africa (21 males, 48 females). Medical history was obtained from the clinic record and by interview. Written informed consent was obtained from all participants as per University of the Witwatersrand Ethics Committee- and Wistar Institute Institutional Review Board-approved study protocol.

Adiposity measurements

Baseline height, weight and anthropometric measurements were obtained pre-ART by trained study personnel; BMI was calculated as weight (kg) divided by height (m)². Dual energy X-ray absorptiometry (DEXA) scans were performed using a Hologic QDR-2000 scanner, assessing limb and trunk fat and lean mass. Magnetic resonance imaging (MRI) scans were performed using a Toshiba Flexart 0.5 T; a single L4-L5 axial section was used to determine sagittal diameter, visceral, subcutaneous, total abdominal and peri-renal fat. The analysis was conducted using V3.51*R553 software.

Clinical laboratory testing

CD4 counts were assessed at baseline (CD4_{BL}, last available measurement prior to ART initiation) and approximately 36 weeks from ART initiation (range 220-259 days; CD4_{END}), using the single platform method described by Scott and Glencross [29]. Serum from fasting blood draws was tested for HDL cholesterol, triglycerides and glucose using a Roche Integra analyzer 400 (Roche Diagnostics, Mannheim, Germany); LDL cholesterol was estimated using the Friedewald formula [30]. HIV-1 infection was confirmed via rapid antibody testing and/or ultra-sensitive PCR, (Roche COBAS Ampliprep/COBAS Amplicor v1.5 methods), with viral load suppression to < 50 copies/ml on ART confirmed every eight weeks.

Immunology measurements

Four-colour flow cytometry stainings to assess immunological parameters were performed on whole blood using custom-made lyoplates (BD Biosciences, Palo Alto, CA). The following antibody combinations were used for the specified target populations: T cell activation/differentiation: CD8, CD28, CD3, CD38; and T cell activation: CD8, CD95, CD3, HLA-DR. After RBC lysis, sample fluorescence data were acquired with a FACScalibur flow cytometer and analyzed using CellQuest software (BD Biosciences). Isotype-matched control antibodies were used as negative controls for gate positioning.

Statistical analysis

Summary statistics (mean, standard deviation, median, min and max) are reported for each independent variable (listed in Table 1) at baseline. Simple linear regression models were fitted to the primary endpoint $\Delta CD4$ ($\Delta CD4 = \text{endpoint CD4 count} - \text{baseline CD4 count}$). Multivariable models were generated using an iterative, stepwise model building procedure, combining forward and backward selection [31]. Differences in time to suppression by BMI category were assessed using a Kaplan Meier test. All statistical tests were performed using R vers. 2.10.0 [32].

Results

Cohort characteristics

The baseline characteristics of our cohort are summarized in Table 1. The median baseline CD4 count ($CD4_{BL}$) was 243 cells/mm³, with a median log₁₀ VL (log₁₀ VL_{BL}) of 4.7. Median BMI was 26.8 kg/m², with

70% of the cohort being overweight or obese (48 of 69 subjects with BMI > 25); median LDL/HDL ratio was 1.8, and median serum fasting glucose was 4.2 mmol/l. According to the Adult Treatment Panel III guidelines [33], 65% of the subjects (45 of 69) had low HDL cholesterol levels [61% < 1 mM (male) or < 1.3 mM (female)], 3% of the subjects had elevated triglycerides (≥ 1.7 mM), 3% had elevated total cholesterol (≥ 5.0 mM), and 7% had elevated LDL cholesterol (≥ 3.0 mM).

After 24 weeks of ART, the median endpoint CD4 count ($CD4_{END}$) was 421 cells/mm³ (interquartile range: 355-505), with a median gain ($\Delta CD4$) of 172 (IQR 92-247) CD4⁺ T cells; five subjects (5.2%) failed to gain CD4 on ART in the presence of viral suppression (immunological failure). As expected, the spread of the distribution in CD4 gain after ART supports the hypothesis that, in addition to viral suppression alone, other factors may determine the extent of immune reconstitution on ART.

Baseline CD4 count, viral load and cellular activation affect immune reconstitution in response to ART

The unadjusted effects of baseline characteristics on ART-mediated immune reconstitution, as measured by $\Delta CD4$ count, are summarized in Table 2. As expected, the effect of log₁₀ VL_{BL} on $\Delta CD4$ was observed to be positive (effect estimate 56.0, corresponding to an increase of 56 CD4⁺ T cells/mm³ in $\Delta CD4$ per log of VL; $p = 0.002$; adjusted $R^2 = 0.12$), suggesting that subjects with high levels of viral replication had the most benefit from pharmacological suppression in terms of CD4 recovery. Conversely, lower baseline $CD4_{BL}$ correlated with higher

Table 1 Baseline (pre-ART) cohort characteristics

| Variable | 25th quantile | Median | 75th quantile | Mean | Standard deviation |
|--|---------------|---------|---------------|---------|--------------------|
| Gender (female/male ratio) | | | 2.29 (48/21) | | |
| Age (years) | 29.0 | 33.0 | 39.0 | 34.6 | 8.2 |
| Baseline CD4 count (cells/mm ³) | 221.0 | 243.0 | 292.0 | 259.8 | 61.6 |
| Baseline log ₁₀ VL | 4.0 | 4.7 | 5.1 | 4.5 | 0.8 |
| Total fat mass (DEXA, g) | 9356.1 | 19451.7 | 28589.5 | 20719.7 | 11801.5 |
| Total lean mass (DEXA, g) | 39458.8 | 42455.1 | 48867.2 | 43582.5 | 6038.0 |
| Fat ratio (DEXA, %) | 16.2 | 32.7 | 39.5 | 29.6 | 12.6 |
| Total abdominal fat (MRI, cm ²) | 144.0 | 294.7 | 414.6 | 311.3 | 191.3 |
| Cholesterol (mmol/L) | 3.1 | 3.5 | 4 | 3.6 | 0.8 |
| HDL-associated cholesterol (mmol/L) | 0.9 | 1.1 | 1.3 | 1.1 | 0.3 |
| LDL-associated cholesterol (mmol/L) | 1.6 | 2.1 | 2.5 | 2.1 | 0.7 |
| Triglycerides (mmol/L) | 0.6 | 0.8 | 1 | 0.8 | 0.3 |
| LDL/HDL cholesterol ratio | 1.5 | 1.8 | 2.6 | 2.3 | 2.7 |
| Waist circumference (cm) | 73.0 | 78.5 | 87.5 | 80.9 | 11.3 |
| Waist/hip ratio | 0.7 | 0.8 | 0.8 | 0.8 | 0.1 |
| Fasting glucose (mmol/l) | 4.0 | 4.2 | 4.4 | 4.3 | 0.6 |
| BMI (kg/m ²) | 24.5 | 26.8 | 29.9 | 28.1 | 5.1 |
| CD95 ⁺ CD8 ⁺ T cells (%) | 81.9 | 89.9 | 95.9 | 85.7 | 14.6 |

Table 2 Association of baseline variables with Δ CD4: model fitting with single variables

| Predictor | Estimate | S.E. | Pr(> t) | Adjusted R ² |
|--|----------|---------|-----------|-------------------------|
| Age | -2.773 | 1.751 | 0.1180 | 0.0217 |
| Sex | -26.283 | 31.231 | 0.4030 | -0.0043 |
| CD4 _{BL} | -0.607 | 0.224 | 0.0085 | 0.0854 |
| Log ₁₀ VL | 56.048 | 17.110 | 0.0017 | 0.1252 |
| Total fat mass (DEXA) | 0.000 | 0.001 | 0.8935 | -0.0147 |
| Total lean mass (DEXA) | -0.002 | 0.002 | 0.3068 | 0.0009 |
| Total fat % (DEXA) | 0.745 | 1.148 | 0.5184 | -0.0086 |
| Total abdominal fat (MRI) | -0.007 | 0.076 | 0.9293 | -0.0148 |
| LDL/HDL ratio | -9.432 | 5.358 | 0.0829 | 0.0299 |
| Waist circumference | -1.128 | 1.281 | 0.3817 | -0.0033 |
| Waist/hip ratio | -458.084 | 183.071 | 0.0148 | 0.0718 |
| Fasting glucose | -28.171 | 23.307 | 0.2310 | 0.0067 |
| BMI | -0.962 | 2.828 | 0.7348 | -0.0132 |
| CD95 ⁺ CD8 ⁺ T cells | 3.136 | 0.919 | 0.0011 | 0.1354 |

Δ CD4 (effect estimate -0.61, corresponding to a decrease of 0.61 CD4⁺ T cells/mm³ in Δ CD4 per unit of CD4_{BL}; $p = 0.008$; $R^2 = 0.08$), indicating a greater benefit of therapy in these subjects.

Baseline levels of CD95⁺ CD8⁺ T cells, an immune activation parameter previously shown to predict pDC recovery on ART [34], had a significant positive effect on Δ CD4 (Table 2; effect estimate 3.14, $p = 0.001$), and had a predictive association with CD4 (adj. $R^2 = 0.13$). We did not detect a significant association of CD38 or HLA-DR expression on CD4⁺ or CD8⁺ T cells with CD4 outcomes (not shown).

Effect of metabolic and anthropometric parameters on immune reconstitution outcomes

As summarized in Table 2 a meaningful negative association with Δ CD4 was observed for waist/hip ratio (effect estimate -458.1, $p = 0.015$, adjusted $R^2 = 0.072$); no association was observed for BMI or gender, suggesting that the relationship is limited to central adiposity, as assessed by waist/hip ratio. LDL/HDL cholesterol ratio (effect estimate -9.432, $p = 0.083$, adjusted $R^2 = 0.03$) was also associated with Δ CD4, unlike other lipid measures (not shown).

To assess if the observed negative effect of central adiposity (i.e., waist/hip ratio) and lipid indicators could be associated with incomplete or delayed suppression of viral load below 50 copies/ml, we compared the proportion of individuals achieving viral suppression (VL < 400 c/ml) over time between normal/underweight, overweight and obese subjects, using a Kaplan-Meier analysis. The survival curves were not significantly different (Figure 1). In addition, we could not detect an association between BMI or waist/hip ratio and time to suppression (not shown). Thus, our data do not support the conclusion that the

negative effect of central adiposity on CD4 immune reconstitution observed in this cohort is caused by differences in rates of virological suppression.

Multivariable analysis of predictors of CD4 recovery on ART


We used a multivariable approach to estimate the combined effect of multiple baseline variables on CD4 recovery on ART. The adjusted R^2 of each model tested is reported in Table 3; together, CD4_{BL} and log₁₀VL_{BL} accounted for approximately 18% of the variability in Δ CD4 (adj. $R^2 = 0.1828$). We also observed a significant interaction between CD4_{BL} and log₁₀VL_{BL} (Figure 2), indicating that the effect of an increase in log₁₀VL_{BL} on Δ CD4 was greater among individuals with lower CD4_{BL} than among individuals with higher CD4_{BL}; modelling this interaction improved the model predictivity to approximately 22% (adj. $R^2 = 0.219$). As CD8⁺ T cell activation has been associated with clinical outcomes in past studies, we tested whether including in this model the frequency of CD95⁺ CD8⁺ T cells, the only activation term individually associated with the Δ CD4 outcome, would improve the predictivity of CD4_{BL} and VL_{BL}: our results indicate an adj. R^2 of 0.2751 for the combined model, supporting the use of an activation term.

The metabolic terms, LDL/HDL cholesterol ratio and waist/hip ratio, together accounted for 11% of Δ CD4 variability (adj. $R^2 = 0.1122$, similar to CD4_{BL} alone); when both metabolic parameters were added to CD4_{BL} and VL_{BL}, the model accounted for almost 37% of Δ CD4 variability (adj. $R^2 = 0.3673$), confirming the role of these metabolic terms as outcome predictors.

The final model, selected for best fit by assessing the models' -2 log likelihood (see Table 4) included CD4_{BL}, log₁₀VL_{BL}, LDL/HDL ratio, waist/hip ratio and CD95⁺ CD8⁺ T cells, in addition to an interaction term between CD4_{BL} and log₁₀VL_{BL}: all of the variables selected had a significant independent effect on the Δ CD4; the interaction CD4_{BL} and log₁₀VL_{BL} also remained significant. This model accounted for almost 44% of the variability in Δ CD4 ($R^2 = 0.4377$), which is approximately twice as much as the best performing CD4_{BL} and log₁₀VL_{BL}-based model, and 1.6 times greater than the model including CD4_{BL}, log₁₀VL_{BL} and CD95 expression. The addition of an interaction term between CD4_{BL} and CD95⁺ CD8⁺ T cells resulted in a further increase of the model predictivity (adj. $R^2 = 0.46$, not shown), but as the effect of the interaction term *per se* was not significant ($p = 0.057$), it was not included in the final model.

Discussion

We report that a multivariable model using pre-ART viral load, immunological parameters and metabolic



variables predicts short-term CD4 recovery in subjects initiating ART to a substantially higher degree than previously reported models. The variability of the extent of immune reconstitution levels (i.e., CD4 gain) in response to ART-mediated viral suppression, confirmed in our cohort, suggests that a number of factors, in addition to successful viral suppression, might affect the extent of immune recovery. Pre-treatment CD4 counts, viral load and immune activation are recognized to play a role in determining the levels of immune recovery [8,10,12,34-36], but individually they have limited usefulness as predictors of early CD4 recovery [9]. All individuals in our cohort received the same ART regimen, thus ruling out effects of post-ART CD4 recovery linked to differences in treatment regimens, as observed in other studies [11].

Our results confirm that pre-ART VL, CD4 count and cellular activation (i.e., CD95 expression [37,38]), alone

or in combination, have a significant, but limited value in predicting the CD4⁺ T cell recovery outcome, explaining only 21% of its variability. The effect of baseline CD4 on Δ CD4 was negative, confirming a prior report [39]; unlike earlier studies [8], we did not assess the effect of baseline CD4⁺ T cell levels on CD4 immune reconstitution, which was found to be positive, as we considered Δ CD4 (a measure incorporating CD4_{BL}) more relevant to assessing an immune reconstitution response. Prior studies have reported an effect of age and gender on CD4 outcomes of treatment [12,27]; while we failed to detect such associations in our cohort, the difference in outcome measured (Δ CD4 vs. CD4 count at endpoint) is likely responsible for this discrepancy.


We found a meaningful negative association between LDL/HDL ratio and CD4⁺ T cell recovery. While this finding is novel, associations of lipid levels and viral replication have been reported [40-43], suggesting the possibility that the observed relationship between LDL/HDL ratios and immune recovery may result in part from direct effects on viral function. A number of studies have demonstrated the effects of membrane cholesterol and lipid rafts on viral penetration and/or budding [44-46]. Moreover, apolipoprotein A1, a component of HDL, has been shown to directly affect the viral life cycle at the viral entry and syncytium formation stages [47-49]). A recent study indicated an association of hypocholesterolemia with a reduced response to ART [50], and studies with cholesterol-lowering agents have shown mixed results [51-56].

Adiposity has generally been associated with better viral control and slower disease progression in ART-naïve, HIV-positive subjects [25,26,57,58]. While in our cohort, BMI did not predict Δ CD4 in response to ART, in keeping with a prior report that did not detect a lack of response to ART in obese subjects [59], we did observe a negative association between waist/hip ratio and CD4 gain, indicating that subjects with low waist to hip ratios (i.e., with low central adiposity) are likely to have better immunologic recovery. One possible

Table 3 Adjusted R² for linear models of Δ CD4

| Variable(s) included as predictors | Adjusted R ² | -2 log Λ L |
|--|-------------------------|--------------------|
| CD4 _{BL} | 0.0854 | 847.28 |
| log ₁₀ VL | 0.1252 | 844.20 |
| CD4 _{BL} + log ₁₀ VL | 0.1828 | 838.47 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) ^a | 0.2190 | 834.29 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) + Waist/hip ratio | 0.2453 | 830.85 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) + LDL/HDL ratio | 0.3380 | 828.08 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) + CD8 ⁺ CD95 ⁺ T cells | 0.2751 | 821.81 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) + LDL/HDL ratio + Waist/hip ratio | 0.3673 | 817.60 |
| CD4 _{BL} + log ₁₀ VL + (CD4 _{BL} × Log ₁₀ VL) + LDL/HDL ratio + Waist/hip ratio + CD8 ⁺ CD95 ⁺ T cells | 0.4377 | 808.36 |

a: interaction term



hypothesis to explain the disconnect between BMI and waist/hip ratio predictive values is that antiretroviral drugs may be metabolized differently or be less bio-available in subjects with higher central adiposity (i.e., high waist/hip ratio). It is also possible that abdominal adipose tissue, particularly the visceral depot, secretes factors that may modulate the effects of the ART or directly interfere with immune reconstitution [60].

While we did not evidence significant differences in time to viral suppression to < 50 c/ml between normal,

overweight and obese subjects (Figure 1), we cannot exclude that metabolic events may be associated with residual levels of viral replication, affecting in turn short-term CD4 recovery. Importantly, the overall HDL-cholesterol values in our cohort were low, with 61% of the subjects being classified as dyslipidemic [33], in keeping with prior reports in HIV-infected African populations [61,62], and there was a high prevalence of overweight/obesity [63] (79% of women and 48% of men had BMI > 25 kg/m²). Based on these observations, as well as the present contribution, further studies in larger cohorts will be necessary to determine if metabolic parameters play the same role in low-central adiposity individuals, and to further explore the relationship between lipids and viral control.

Altogether our data indicate that metabolic parameters contribute to predicting the degree of immune reconstitution achieved upon viral suppression. While our study does not address the pathophysiologic mechanisms underlying this relationship, prior reports indicate that fat accumulation promotes low-level inflammation, which, in turn, has been shown to be associated with lack of immunologic reconstitution [38], suggesting a possible biological pathway.

By including pre-ART metabolic parameters in conjunction with baseline CD4, viral load and immune activation, our final model accounts for 44% of the variability in CD4⁺ T cell gain in response to viral suppression, representing, to our knowledge, the best predictive model on immune reconstitution to date, and represents a marked improvement over more conventional assessments (e.g., baseline CD4⁺ T cell counts alone or with viral load).

While not designed to support clinical interventions, our results, if supported by validation in a larger cohort, suggest the testable hypothesis that clinical and behavioural interventions aimed at reducing weight in subjects with central adiposity, as well as pharmacological intervention aimed at improving LDL/HDL ratios (e.g., statins), might improve the immunological outcomes or ART, at least in the short term.

As with all modeling techniques, there are limitations to our findings. In the first place, we modeled the effect of the assessed variables on the change in CD4 between baseline and six months on ART: it remains to be determined if incorporating multiple early CD4 measurements would improve the predictivity of the model. Moreover, the predictive value of the model will have to be validated in a larger independent cohort.

In addition, due to the relatively small size of the study, we did not assess the effect of clinical conditions that could affect some of the parameters studied here (e.g., hypertension, diabetes).

As we gain a more accurate estimate of response to ART, it remains to be determined, through further

Table 4 Multivariable analysis: complete model parameter estimates

| Coefficient | Estimate | Standard error | p |
|--|-----------|----------------|--------|
| Intercept | -721.3331 | 372.7459 | 0.0575 |
| CD4 _{BL} | 2.8829 | 1.2345 | 0.0228 |
| $\log_{10}VL_{BL}$ | 238.3317 | 72.7549 | 0.0017 |
| CD4 _{BL} × $\log_{10}VL_{BL}$ | -0.7369 | 0.2753 | 0.0095 |
| LDL/HDL ratio | -17.3449 | 4.2669 | 0.0001 |
| Waist/hip ratio | -294.0370 | 146.6771 | 0.0494 |
| CD95 ⁺ CD8 ⁺ T cells | 2.3330 | 0.7827 | 0.0041 |

Adjusted R² = 0.4377

studies, how each variable impacts CD4 recovery mechanistically and whether additional predictors may improve the reliability of the prediction.

Conclusions

We report for the first time that metabolic markers can contribute significantly to the variability of immune reconstitution outcomes following ART initiation in a cohort of HIV-1-infected South African subjects. While the current study clearly establishes the predictive potential for metabolic markers, further studies will be required to determine the cost effectiveness of this predictive approach, and to determine whether additional longitudinal measurement would further improve the model performance.

Acknowledgements and funding

This work was partially supported by: NIH/NIAID grant U01AI51986 to LJM; NIH/NIAID grant RO1 AI069996 to LA; and NIH/NIAID grant RO1 AI056983 to ASF. Additional support was provided by The Philadelphia Foundation (Robert I. Jacobs Fund), The Stengel-Miller family, AIDS funds from the Commonwealth of Pennsylvania and from the Commonwealth Universal Research Enhancement Program, Pennsylvania Department of Health, as well as by a Cancer Center Grant (P30 CA10815).

Author details

¹HIV-1 Immunopathogenesis Laboratory, the Wistar Institute, Philadelphia, PA, USA. ²School of Public Health and Health Sciences, University of Massachusetts, Amherst, USA. ³Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. ⁴Department of Chemical Pathology, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa. ⁵Department of Hematology and Molecular Medicine, National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa.

Authors' contributions

LA was responsible for study design, data management, data analysis, and manuscript and illustration preparation. ASF supervised the statistical analysis, and contributed to data discussion and manuscript preparation. CF was responsible for clinical coordination and patient interaction, and contributed to data discussion and manuscript revision. XY was responsible for statistical analysis, and contributed to data discussion and manuscript revision. NJC was responsible for lipid assessment, and contributed to critical analysis, data discussion and manuscript preparation. DG was responsible for flow cytometry supervision, and contributed to data discussion and manuscript revision. DL was responsible for flow cytometry analysis and CD4 assessment, and contributed to manuscript revision. WS was responsible for clinical laboratory supervision, and contributed to data discussion and manuscript preparation. EP contributed to data discussion and manuscript revision. IS was responsible for supervising clinical coordination and patient interaction, and contributed to data discussion and manuscript preparation. LJM was responsible for supervising immunology laboratory assessments, and contributed to study design, critical analysis and manuscript preparation. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 6 December 2010 Accepted: 29 July 2011

Published: 29 July 2011

References

1. Azzoni L, Chehimi J, Zhou L, Foulkes AS, June R, Maino VC, Landay A, Rinaldo C, Jacobson LP, Montaner LJ: **Early and delayed benefits of HIV-1**

- suppression: timeline of recovery of innate immunity effector cells. *AIDS* 2007, **21**:293-305.
2. Coetzee LM, Tay SS, Lawrie D, Janossy G, Glencross DK: **From research tool to routine test: CD38 monitoring in HIV patients.** *Cytometry B Clin Cytom* 2009, **76**:375-384.
3. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, Abrams DI, MacArthur RD, Henry K, Neaton JD: **Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases.** *J Acquir Immune Defic Syndr* 2008, **48**:541-546.
4. Bonnet F, Thiebaut R, Chene G, Neau D, Pellegrin JL, Mercie P, Beylot J, Dabis F, Salamon R, Morlat P: **Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy.** Aquitaine Cohort, France, 1996-2002. *HIV Med* 2005, **6**:198-205.
5. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M, Antiretroviral Therapy (ART) Cohort Collaboration: **Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.** *Lancet* 2002, **360**:119-129.
6. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R: **Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.** *AIDS* 2005, **19**:2141-2148.
7. Le Moing V, Thiebaut R, Chene G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaied F, Leport C, Raffi F: **Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently < 500 copies/mL during treatment with antiretroviral drugs.** *HIV Med* 2007, **8**:156-163.
8. De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Gueye NF, Gueye PM, Sow PS, Mboup S, Ndoye I, Ecochard R, Eric D: **Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.** *Am J Trop Med Hyg* 2009, **80**:1047-1053.
9. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczar D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA, Antiretroviral Therapy Cohort Collaboration: **Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.** *J Acquir Immune Defic Syndr* 2009, **52**:357-363.
10. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, Mellors JW, Wolinsky SM, Jacobson LP: **Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.** *AIDS* 2001, **15**:735-746.
11. Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD: **Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.** *AIDS* 2006, **20**:1141-1150.
12. Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A: **Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study.** *HIV Med* 2003, **4**:255-262.
13. Appay V, Sauce D: **Immune activation and inflammation in HIV-1 infection: causes and consequences.** *J Pathol* 2008, **214**:231-241.
14. Azzoni L, Pappasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ: **Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity.** *J Immunol* 2002, **168**:5764-5770.
15. Azzoni L, Rutstein RM, Chehimi J, Farabaugh MA, Nowmos A, Montaner LJ: **Dendritic and natural killer cell subsets associated with stable or declining CD4+ cell counts in treated HIV-1-infected children.** *J Infect Dis* 2005, **191**:1451-1459.
16. Chehimi J, Campbell DE, Azzoni L, Bacheller D, Pappasavvas E, Jerandi G, Mounzer K, Kostman J, Trinchieri G, Montaner LJ: **Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.** *J Immunol* 2002, **168**:4796-4801.
17. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, Streeck H, Johnston MN, Staller KD, Zaman MT, Yu XG, Lichterfeld M, Basgoz N, Rosenberg ES, Altfeld M: **Sequential deregulation of NK cell subset**

- distribution and function starting in acute HIV-1 infection. *Blood* 2005, **106**:3366-3369.
18. Kaplan RC, Kingsley LA, Gange SJ, Benning L, Jacobson LP, Lazar J, Anastos K, Tien PC, Sharrett AR, Hodis HN: **Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men.** *AIDS* 2008, **22**:1615-1624.
 19. Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, Nappa S, Valvano A, Leonardi E, Borgia G, Castello G, Napoli R, Saccà L: **Human immunodeficiency virus per se exerts atherogenic effects.** *Atherosclerosis* 2009, **204**:586-589.
 20. Fernandez-Miranda C, Pulido F, Carrillo JL, Larumbe S, Gomez Izquierdo T, Ortuno B, Rubio R, del Palacio A: **Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers.** *Clin Chim Acta* 1998, **274**:63-70.
 21. El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS: **Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort.** *HIV Med* 2005, **6**:114-121.
 22. Treitinger A, Spada C, da Silva LM, Hermes EM, Amaral JA, Abdalla DS: **Lipid and acute-phase protein alterations in HIV-1 infected patients in the early stages of infection: correlation with CD4+ lymphocytes.** *Braz J Infect Dis* 2001, **5**:192-199.
 23. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D: **HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment.** *Metabolism* 2006, **55**:90-95.
 24. Francisci D, Giannini S, Baldelli F, Leone M, Belfiori B, Guglielmini G, Malincarne L, Gresele P: **HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.** *AIDS* 2009, **23**:589-596.
 25. Shuter J, Chang CJ, Klein RS: **Prevalence and predictive value of overweight in an urban HIV care clinic.** *J Acquir Immune Defic Syndr* 2001, **26**:291-297.
 26. Shor-Posner G, Campa A, Zhang G, Persaud N, Baum MK: **Obesity and immune function in the Miami HIV-1 infected drug abusers study.** *J Am Diet Assoc* 1999, **99**:1512.
 27. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M: **Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.** *AIDS* 2008, **22**:2291-2302.
 28. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M: **Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500 cells/microl in HIV type 1-infected individuals receiving potent antiretroviral therapy.** *Clin Infect Dis* 2005, **41**:361-372.
 29. Glencross DK, Janossy G, Coetzee LM, Lawrie D, Aggett HM, Scott LE, Sanne I, McIntyre JA, Stevens W: **Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS.** *Cytometry B Clin Cytom* 2008, **74**(Suppl 1):S40-51.
 30. Friedewald WT, Levy RI, Fredrickson DS: **Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.** *Clin Chem* 1972, **18**:499-502.
 31. Collett D: **Modeling Survival Data in Medical Research.** In *Modeling Survival Data in Medical Research. Volume 83.* Chapman & Hall/CRC Press; 2003.
 32. Team RDC: **In R: A language and environment for statistical computing.** Edited by: Vienna, Austria. R Foundation for Statistical Computing; 2008.
 33. **Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).** *JAMA* 2001, **285**:2486-2497.
 34. Chehimi J, Azzoni L, Farabaugh M, Creer SA, Tomescu C, Hancock A, Mackiewicz A, D'Alessandro L, Ghanekar S, Foulkes AS, Mounzer K, Kostman J, Montaner LJ: **Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.** *J Immunol* 2007, **179**:2642-2650.
 35. Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM: **CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.** *Clin Immunol* 2002, **102**:154-161.
 36. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts NJ Jr, Currier JS, AIDS Clinical Trials Group 889 Study Team: **Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.** *J Infect Dis* 2003, **188**:1794-1803.
 37. Almeida M, Cordero M, Almeida J, Orfao A: **Persistent abnormalities in peripheral blood dendritic cells and monocytes from HIV-1-positive patients after 1 year of antiretroviral therapy.** *J Acquir Immune Defic Syndr* 2006, **41**:405-415.
 38. Mavigner M, Delobel P, Cazabat M, Dubois M, L'Faqihi-Olive FE, Raymond S, Pasquier C, Marchou B, Massip P, Izopet J: **HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.** *PLoS One* 2009, **4**:e7658.
 39. Wu H, Connick E, Kuritzkes DR, Landay A, Spritzler J, Zhang B, Spear GT, Kessler H, Lederman MM: **Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.** *AIDS Res Hum Retroviruses* 2001, **17**:1231-1240.
 40. Grunfeld C, Pang M, Doerfler W, Shigenaga JK, Jensen P, Feingold KR: **Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.** *J Clin Endocrinol Metab* 1992, **74**:1045-1052.
 41. Aragones G, Beltran-Debon R, Rull A, Rodriguez-Sanabria F, Fernandez-Sender L, Camps J, Joven J, Alonso-Villaverde C: **Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity.** *Clin Chem Lab Med* 2008, **46**:1147-1152.
 42. Grunfeld C: **Dyslipidemia and its Treatment in HIV Infection.** *Top HIV Med* 2006, **18**:112-118.
 43. Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A, Sviridov D: **HIV infection and high density lipoprotein metabolism.** *Atherosclerosis* 2008, **199**:79-86.
 44. Liao Z, Cimaskasy LM, Hampton R, Nguyen DH, Hildreth JE: **Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1.** *AIDS Res Hum Retroviruses* 2001, **17**:1009-1019.
 45. Popik W, Alce TM, Au WC: **Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells.** *J Virol* 2002, **76**:4709-4722.
 46. Nguyen DH, Hildreth JE: **Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.** *J Virol* 2000, **74**:3264-3272.
 47. Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP: **Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.** *J Clin Invest* 1990, **86**:1142-1150.
 48. Martin I, Dubois MC, Saermark T, Ruysschaert JM: **Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HIV (human immunodeficiency virus) GP41: implications in viral entry.** *Biochem Biophys Res Commun* 1992, **186**:95-101.
 49. Alonso-Villaverde C, Segues T, Coll-Crespo B, Perez-Bernalte R, Rabassa A, Gomila M, Parra S, Gozalez-Esteban MA, Jimenez-Exposito MJ, Masana L: **High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy.** *AIDS* 2003, **17**:1173-1178.
 50. Miguez MJ, Lewis JE, Bryant VE, Rosenberg R, Burbano X, Fishman J, Asthana D, Duan R, Madhavan N, Malow RM: **Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study.** *J Int AIDS Soc* 2005, **13**:25.
 51. Sklar PA, Masur H, Grubb JR, Voell J, Witek J, Ono A, Freed EO, Maldarelli F: **Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.** *AIDS* 2005, **19**:1109-1111.
 52. Moncunill G, Negro E, Bosch L, Vilarasa J, Witvrouw M, Llano A, Clotet B, Este JA: **Evaluation of the anti-HIV activity of statins.** *AIDS* 2005, **19**:1697-1700.
 53. Manfredi R, Calza L, Chiodo F: **Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART.** *AIDS* 2006, **20**:455-457.
 54. Rodriguez B, Valdez H, Mijch A, Watson K, Lederman MM, McCormsey GA, Loupa CV, Woolley I: **Statins Blunt HAART-Induced CD4 T-Cell Gains but**

- Have No Long-Term Effect on Virologic Response to HAART. *J Int Assoc Physicians AIDS Care (Chic Ill)* 2007, **6**:198-202.
55. Negrodo E, Puigdomenech I, Marfil S, Puig J, Perez-Alvarez N, Ruiz L, Rey-Joly C, Clotet B, Blanco J: **Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.** *J Antimicrob Chemother* 2008, **61**:400-404.
 56. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, Gomez-Mouton C, Alegret M, Pena JM, Rodriguez-Zapata M, Alvarez-Mon M, Martínez-A C, Mañes S: **Statins inhibit HIV-1 infection by down-regulating Rho activity.** *J Exp Med* 2004, **200**:541-547.
 57. Jones CY, Hogan JW, Snyder B, Klein RS, Rompalo A, Schuman P, Carpenter CC: **Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort.** *Clin Infect Dis* 2003, **37**(Suppl 2):S69-80.
 58. Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A: **HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival.** *Int J Epidemiol* 2005, **34**:577-584.
 59. Tedaldi EM, Brooks JT, Weidle PJ, Richardson JT, Baker RK, Buchacz K, Moorman AC, Wood KC, Holmberg SD: **Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients.** *J Acquir Immune Defic Syndr* 2006, **43**:35-41.
 60. Hamdy O, Porramatikul S, Al-Ozairi E: **Metabolic obesity: the paradox between visceral and subcutaneous fat.** *Curr Diabetes Rev* 2006, **2**:367-373.
 61. Anastos K, Ndamage F, Lu D, Cohen MH, Shi Q, Lazar J, Bigirimana V, Mutimura E: **Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women.** *AIDS Res Ther* 7:34.
 62. George JA, Venter WD, Van Deventer HE, Crowther NJ: **A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine.** *AIDS Res Hum Retroviruses* 2009, **25**:771-781.
 63. Puoane T, Steyn K, Bradshaw D, Laubscher R, Fourie J, Lambert V, Mbananga N: **Obesity in South Africa: the South African demographic and health survey.** *Obes Res* 2002, **10**:1038-1048.

doi:10.1186/1758-2652-14-37

Cite this article as: Azzoni et al.: Metabolic and anthropometric parameters contribute to ART-mediated CD4⁺ T cell recovery in HIV-1-infected individuals: an observational study. *Journal of the International AIDS Society* 2011 **14**:37.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

